| Methods |
Blinding of randomization: yes
Blinding of intervention: yes
Complete follow up: unclear
Blinding of outcome: yes
Double blind trial; cross‐over design with pooled data
No washout period documented |
| Participants |
Patients entered into the study: n=10
Entry criteria: BPD.
Ten patients were randomized. Postnatal age ranged between 23 and 101 days, and average FiO2 was 0.27±0.13. Baseline compliance during the furosemide period tended to be 26% lower than during the placebo period (1.14±0.79 ml/cm vs 1.55±1.04 ml/cm, respectively, NS). |
| Interventions |
Furosemide vs placebo
Patients were randomly allocated to receive either furosemide 1.5 mg/kg IM q 12 hours for 3 doses, or placebo. |
| Outcomes |
Main outcome: compliance and ventilation.
The authors report that furosemide produced a significant increase in compliance, a 6‐fold increase in urine output, an increase in serum solids and no significant change in serum Na and K concentrations.
Compliance was 1.38±0.79 ml/cm after the third dose of furosemide, compared with 1.54±0.98 after the third dose of placebo. We found no significant difference between the two periods in compliance expressed in % of baseline. |
| Notes |
(1) Abstract form only; incomplete information available. Standard error was mentioned for compliance but not for other variables.
(2) Neither 'random', 'randomized' or 'randomly' is mentioned in the text. Nevertheless, this is a double‐blind clinical trial, so that the we assumed this was a randomized trial.
3) Compliance was measured 2 hours after the third dose of furosemide. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Double blind trial; cross‐over design with pooled data |
| Allocation concealment (selection bias) |
Low risk |
Blinding of randomization: yes |
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
Blinding of intervention: yes
Blinding of outcome: yes |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Complete follow up: unclear |
